Cameron D. Wright
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Cameron D. Wright has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Jeanne B. Ackman
Harvard Medical School & Massachusetts General Hospital
2 shared publications - Abner Louissaint
Department of Pathology, Massachusetts General Hospital, Boston, MA USA
1 shared publication Akash Premkumar
Department of Surgery, Harvard Medical School, Boston, MA, USA
1 shared publication- Alexandra E. Kovach
Massachusetts General Hospital, Harvard Medical School, United States
1 shared publication - Alison S. Witkin
Department of Pulmonary and Critical Care Medicine Massachusetts General Hospital Boston MA USA
1 shared publication Andrea L. Axtell
Massachusetts General Hospital
1 shared publication
Latest Publications
- 28 May 2025
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 171 (1) , 314-315
Continuing Certification for Diplomates of the American Board of Thoracic Surgery
- 28 May 2025
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 171 (1) , 314-315
Continuing Certification for Diplomates of the American Board of Thoracic Surgery
- 10 November 2024
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 120 (2) , 281-282
Carinal Resections—Not for the Faint of Heart
- 10 November 2024
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 120 (2) , 281-282
Carinal Resections—Not for the Faint of Heart
- 25 January 2024
- Published by Springer Nature
- p. 275-282
Acute and Chronic Pulmonary Embolism
- 22 December 2022
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 116 (4) , 711
Should oncogene testing be performed before induction immunotherapy?
- 22 December 2022
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 116 (4) , 711
Should oncogene testing be performed before induction immunotherapy?
- 1 July 2022
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 164 (1) , 287-288
Commentary: Reconfiguring the airway with the robot to improve patients' quality of life
- 1 July 2022
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 164 (1) , 287-288
Commentary: Reconfiguring the airway with the robot to improve patients' quality of life
- 1 August 2021
- Published by Elsevier in Thoracic Surgery Clinics
- Vol. 31 (3) , 273-281
Extended Pulmonary Resection by Sleeve Lobectomy and Carinal Pneumonectomy
- 1 August 2021
- Published by Elsevier in Thoracic Surgery Clinics
- Vol. 31 (3) , 273-281
Extended Pulmonary Resection by Sleeve Lobectomy and Carinal Pneumonectomy
- 2 July 2021
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 35 (1)
Management and outcomes of esophageal perforation
Esophageal perforation is a morbid condition and remains a therapeutic challenge. We report the outcomes of a large institutional experience with esophageal perforation and identify risk factors for morbidity and mortality. A retrospective analysis was conducted on 142 patients who presented with a thoracic or gastroesophageal junction esophageal perforation from 1995 to 2020. Baseline characteristics, operative or interventional strategies, and outcomes were analyzed by etiology of the perforation and management approach. Multivariable cox and logistic regression models were constructed to identify predictors of mortality and morbidity. Overall, 109 (77%) patients underwent operative intervention, including 80 primary reinforced repairs and 21 esophagectomies and 33 (23%) underwent esophageal stenting. Stenting was more common in iatrogenic (27%) and malignant (64%) perforations. Patients who presented with a postemetic or iatrogenic perforation had similar 90-day mortality (16% and 16%) and composite morbidity (51% and 45%), whereas patients who presented with a malignant perforation had a 45% 90-day mortality and 45% composite morbidity. Risk factors for mortality included age >65 years (hazard ratio [HR] 1.89 [1.02–3.26], P = 0.044) and a malignant perforation (HR 4.80 [1.31–17.48], P = 0.017). Risk factors for composite morbidity included pleural contamination (odds ratio [OR] 2.06 [1.39–4.43], P = 0.046) and sepsis (OR 3.26 [1.44–7.36], P = 0.005). Of the 33 patients who underwent stent placement, 67% were successfully managed with stenting alone and 30% required stent repositioning. Risk factors for morbidity and mortality after esophageal perforation include advanced age, pleural contamination, septic physiology, and malignant perforation. Primary reinforced repair remains a reasonable strategy for patients with an esophageal perforation from a benign etiology.
- 2 July 2021
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 35 (1)
Management and outcomes of esophageal perforation
Esophageal perforation is a morbid condition and remains a therapeutic challenge. We report the outcomes of a large institutional experience with esophageal perforation and identify risk factors for morbidity and mortality. A retrospective analysis was conducted on 142 patients who presented with a thoracic or gastroesophageal junction esophageal perforation from 1995 to 2020. Baseline characteristics, operative or interventional strategies, and outcomes were analyzed by etiology of the perforation and management approach. Multivariable cox and logistic regression models were constructed to identify predictors of mortality and morbidity. Overall, 109 (77%) patients underwent operative intervention, including 80 primary reinforced repairs and 21 esophagectomies and 33 (23%) underwent esophageal stenting. Stenting was more common in iatrogenic (27%) and malignant (64%) perforations. Patients who presented with a postemetic or iatrogenic perforation had similar 90-day mortality (16% and 16%) and composite morbidity (51% and 45%), whereas patients who presented with a malignant perforation had a 45% 90-day mortality and 45% composite morbidity. Risk factors for mortality included age >65 years (hazard ratio [HR] 1.89 [1.02–3.26], P = 0.044) and a malignant perforation (HR 4.80 [1.31–17.48], P = 0.017). Risk factors for composite morbidity included pleural contamination (odds ratio [OR] 2.06 [1.39–4.43], P = 0.046) and sepsis (OR 3.26 [1.44–7.36], P = 0.005). Of the 33 patients who underwent stent placement, 67% were successfully managed with stenting alone and 30% required stent repositioning. Risk factors for morbidity and mortality after esophageal perforation include advanced age, pleural contamination, septic physiology, and malignant perforation. Primary reinforced repair remains a reasonable strategy for patients with an esophageal perforation from a benign etiology.
- 25 June 2018
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 156 (4) , 1702-1703
Navigating the lung for hidden treasure
- 25 June 2018
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 156 (4) , 1702-1703
Navigating the lung for hidden treasure
- 1 May 2018
- Published by Elsevier in Thoracic Surgery Clinics
- Vol. 28 (2) , 243-247
Nonoperative Endoscopic Management of Benign Tracheobronchial Disorders
- 1 May 2018
- Published by Elsevier in Thoracic Surgery Clinics
- Vol. 28 (2) , 243-247
Nonoperative Endoscopic Management of Benign Tracheobronchial Disorders
- 1 May 2018
- Published by Elsevier in Thoracic Surgery Clinics
- Vol. 28 (2) , 163-166
Tracheobronchomalacia and Expiratory Collapse of Central Airways
- 1 May 2018
- Published by Elsevier in Thoracic Surgery Clinics
- Vol. 28 (2) , 163-166
Tracheobronchomalacia and Expiratory Collapse of Central Airways